Author： Keating Gillian M. Robinson Dean M.
Publisher： Adis International
ISSN： 1172-7047
Source： CNS Drugs, Vol.21, Iss.8, 2007-01, pp. : 695-697
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Quetiapine (Seroquel®) is the only atypical antipsychotic approved in the US for use as monotherapy in both bipolar mania and depression, offering potential compliance advantages. Monotherapy with oral quetiapine 300 mg/day is effective in the treatment of patients with bipolar I or II depression. Rapid and sustained improvements in depressive and anxiety symptoms are seen with quetiapine, as well as improvements in health-related quality of life. Quetiapine is generally well tolerated in bipolar depression and is not associated with an increased risk of treatment-emergent mania. Thus, despite the current lack of data from active comparator trials, quetiapine monotherapy should be considered a first-line option for the acute treatment of bipolar depression.
Related content
Access to resources
Recommend
Quetiapine monotherapy for bipolar depression
By Janicak Philip G Rado Jeffrey T
Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 10, 2011-07 ,pp. :
Quetiapine goes boldly on in bipolar depression
Inpharma, Vol. 1, Iss. 1517, 2005-01 ,pp. :
Quetiapine: a guide to its use in bipolar depression
Drugs & Therapy Perspectives, Vol. 23, Iss. 12, 2007-12 ,pp. :
Quetiapine: A Review of its Use in the Treatment of Bipolar Depression
By Keating Gillian M. Robinson Dean M.
Drugs, Vol. 67, Iss. 7, 2007-01 ,pp. :